Biomea Fusion (BMEA)
(Real Time Quote from BATS)
$4.56 USD
-0.65 (-12.48%)
Updated Jun 26, 2024 01:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
BMEA 4.56 -0.65(-12.48%)
Will BMEA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BMEA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMEA
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
BMEA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
Other News for BMEA
Biomea Fusion initiated with neutral view at Rodman & Renshaw
Buy Rating Affirmed for Biomea Fusion Amid Temporary Clinical Hold and Positive Outlook
Biomea Fusion Hold Recommendation Amid Clinical Setbacks and Rising Competition
Largest borrow rate increases among liquid names
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session